Revvity announced the launch of pHSense reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization.

Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to-background—even at low endogenous receptor expression levels.

Fully compatible with Revvity’s multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows.

By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation.

“pHSense reagents fill a critical gap in internalization assay technologies, directed towards enabling researchers to gain faster, more reliable insights using more physiologically relevant conditions,” said Craig Monell, senior vice president, reagents at Revvity. “With this launch, Revvity reinforces its commitment to advancing drug discovery through innovative tools that are focused on improving data quality, throughput, and reproducibility.”